Company profile MBRX

Moleculin Biotech Inc
moleculin biotech, inc. is a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at m.d. anderson cancer center. our lead product candidate is annamycin, a phase ii clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as aml.... we also have two pre-clinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient’s own immune system. the other portfolio targets the metabolism of tumors. Show More
Quarter analysis & expected interestLast update: February 08 2024 01:09:50.

After 38 days of this quarter the interest is at 6.0. Based on that we can calculate that during remaining 53 days it will total up to 14.0.
Moleculin Biotech expected interest is significantly lower compared to previous quarter (-65.0%) and same quarter last year (-72.5%).

YearQ1Q2Q3Q4
20199
99
1000.0% QoQ
22
-77.8% QoQ
0
-100.0% QoQ
2020 106
1077.8% YoY inf% QoQ
372
275.8% YoY 250.9% QoQ
111
404.5% YoY -70.2% QoQ
33
inf% YoY -70.3% QoQ
2021 147
38.7% YoY 345.5% QoQ
61
-83.6% YoY -58.5% QoQ
6
-94.6% YoY -90.2% QoQ
15
-54.5% YoY 150.0% QoQ
2022 12
-91.8% YoY -20.0% QoQ
8
-86.9% YoY -33.3% QoQ
23
283.3% YoY 187.5% QoQ
24
60.0% YoY 4.3% QoQ
2023 51
325.0% YoY 112.5% QoQ
32
300.0% YoY -37.3% QoQ
34
47.8% YoY 6.2% QoQ
40
66.7% YoY 17.6% QoQ
2024 6
-88.2% YoY -85.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Moleculin Biotech search interestLast update: February 08 2024 01:09:50.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 01:09:51.

The average 5 years interest of Moleculin Biotech was 4.64 per week.
The last year interest of Moleculin Biotech compared to the last 5 years has changed by -37.5%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by 8.61%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Annamycin for leukemia to provide analysis

Correlation between past revenue and Annamycin for leukemia search interest

There is not enough data for Annamycin for leukemia to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Annamycin for leukemia to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for WP1066 brain tumors to provide analysis

Correlation between past revenue and WP1066 brain tumors search interest

There is not enough data for WP1066 brain tumors to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for WP1066 brain tumors to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for WP1220 cutaneous T-cell lymphoma to provide analysis

Correlation between past revenue and WP1220 cutaneous T-cell lymphoma search interest

There is not enough data for WP1220 cutaneous T-cell lymphoma to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for WP1220 cutaneous T-cell lymphoma to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for WP1122 glioblastoma multiforme to provide analysis

Correlation between past revenue and WP1122 glioblastoma multiforme search interest

There is not enough data for WP1122 glioblastoma multiforme to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for WP1122 glioblastoma multiforme to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Moleculin Biotech stock. to provide analysis

Correlation between past revenue and Moleculin Biotech stock. search interest

There is not enough data for Moleculin Biotech stock. to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Moleculin Biotech stock. to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for MBRX
Earnings date: 2024-03-20 After close
Company name: Moleculin Biotech Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-13T12:00:00Z

GlobeNewswire
Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks

2026-05-12T13:30:00Z

GlobeNewswire
Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits

2026-05-08T12:45:00Z

GlobeNewswire
Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin

2026-04-23T12:25:00Z

GlobeNewswire
Moleculin's Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026

2026-04-21T12:36:00Z

GlobeNewswire
Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting

2026-04-07T12:36:00Z

GlobeNewswire
Moleculin Releases Next CEO Corner Segment Highlighting Annamycin's Non-Cardiotoxic Profile

2026-03-27T09:15:00-04:00

PR Newswire
Scalable Biotech Manufacturing Unlocks a $14B Market

2026-03-24T14:02:04Z

Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on Moleculin Biotech, Maintains $22 Price Target

2026-03-23T12:31:00Z

GlobeNewswire
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout

2026-02-19T13:39:00Z

GlobeNewswire
Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds

2026-02-18T13:20:00Z

GlobeNewswire
Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)

2026-02-17T13:35:00Z

GlobeNewswire
Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin

2026-02-13T13:32:00Z

GlobeNewswire
Moleculin Launches CEO Corner Platform to Share Strategic Insights

2026-02-09T16:30:00Z

AccessWire
JTC Team Companies to Present in Webull Corporate Connect Webinar Series Happening February 10-11, 2026

2026-02-05T14:15:00Z

GlobeNewswire
Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial